Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Coya Therapeutics, Inc.NASDAQ: COYA

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 46.8% from a year ago

Total equity stood at $48.97M at the end of Q1 FY2026, up 46.8% from a year earlier and up 13.8% from the prior quarter.

Context

  • Total equity amounted to 91.9% of total assets at the end of Q1 FY2026, up 5.0 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +46.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48.97M+13.8% QoQ
Last fiscal yearDec 2025
$43.03M+8.7% YoY
Year agoMar 2025
$33.37M+46.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.8%——
1 year+8.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
43.03M USD
Year-over-year change
+8.7%
4-year CAGR
+85.4%

Total Equity vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's Mar 2026 total equity of $48.97M is the 9th highest of the 11 companies compared; the peer median is $106.01M.
  • Its year-over-year change of +46.8% is the 4th highest of 11, against a peer median of -37.0%.
  • Total equity amounts to 91.9% of total assets for COYA, versus a peer median of 88.0%.
COYA Competitors Peer median
Total Equity for COYA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORMPOramed Pharmaceuticals Inc.Mar 2026$238.28M +70.3%+9.7%88.6%
OVIDOvid Therapeutics Inc.Mar 2026$198.27M +234.5%-0.4%87.9%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$182.68M -38.2%-20.7%72.2%
PLRXPliant Therapeutics, Inc.Mar 2026$165.17M -35.8%-16.7%81.5%
WHWKWhitehawk Therapeutics IncMar 2026$116.18M -47.6%-4.9%91.3%
STTKShattuck Labs, Inc.Mar 2026$95.84M +41.8%-22.4%93.8%
IMMXImmix Biopharma, Inc.Mar 2026$84.36M +779.4%+92.4%88.0%
CNTXContext Therapeutics Inc.Mar 2026$52.2M -42.6%+20.3%88.7%
COYACoya Therapeutics, Inc.Mar 2026$48.97M +46.8%—91.9%
MGNXMacroGenics, Inc.Mar 2026$21.2M -73.2%-26.8%9.7%
CLNNClene Inc.Mar 2026-$18.81M -278.2%—86.8%
Peer median (excluding COYA) $106.01M-37.0%-4.9%88.0%

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.34M5.93M32.63M38.34M46.82M
Short-term Investments00000
Net Receivables007.5M730.58K0
Inventory00000
Other Current Assets00000
Total Current Assets4.58M7.18M41.2M44.31M49.94M
Property, Plant & Equipment (Net)120.67K93.31K65.95K38.59K11.23K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets87.18K1.12M000
Total Non-current Assets207.85K1.21M65.95K38.59K11.23K
Total Assets4.79M8.4M41.26M44.35M49.95M
Account Payables857.57K1.82M1.16M1.59M1.06M
Short-term Debt00000
Tax Payables00723.85K00
Deferred Revenue00923.11K848.29K1.2M
Other Current Liabilities00000
Total Current Liabilities1.15M3.82M5.05M3.82M5.87M
Long-term Debt012.97M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00574.69K945.45K1.05M
Other Non-current Liabilities00000
Total Non-current Liabilities012.97M574.69K945.45K1.05M
Total Liabilities1.15M16.79M5.63M4.77M6.92M
Common Stock2592591.44K1.67K2.09K
Retained Earnings(5.62M)(17.87M)(25.86M)(40.74M)(61.96M)
Accumulated OCI00000
Other Stockholders Equity00(11.25K)00
Minority Interest00000
Total Equity3.64M(8.39M)35.64M39.58M43.03M
Total Debt012.97M000
Net Debt(4.34M)7.03M(32.63M)(38.34M)(46.82M)

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.